XETR
MRK
Market cap363bUSD
, Last price
EUR
Name
Merck & Co Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Related entities
Subsidiaries (22)
Merck Sharp & Dohme LLC
ALLFLEX INDIA PRIVATE LIMITED
INTERVET INDIA PRIVATE LIMITED
MERCK HOLDINGS LLC
Merck International Holdings LLC
MERCK SHARP & DOHME B.V.
MERCK SHARP & DOHME FINANCE EUROPE LIMITED
MERCK SHARP & DOHME MANUFACTURING UNLIMITED COMPANY
MERCK SHARP & DOHME RESEARCH GMBH
MSD ANIMAL HEALTH PENSION SCHEME
MSD FI B.V.
MSD FINANCE 2 LLC
MSD FINANCE B.V.
MSD Human Health Holding B.V.
MSD HYDERABAD GLOBAL CAPABILITIES CENTER INDIA PRIVATE LIMITED
MSD INTERNATIONAL BUSINESS GMBH
MSD INTERNATIONAL FINANCE B.V.
MSD INTERNATIONAL GMBH
MSD Netherlands Capital B.V.
MSD Pharmaceuticals Investments 3
Key people
Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division · since 2016
Richard R. DeLuca
Executive Vice President, President - Merck Animal Health · since 2011
Michael T. Nally
Executive Vice President, Chief Marketing Officer · since 2019
Michael W. Fleming
Senior Vice President, Chief Ethics and Compliance Officer · since 2019
Executive Vice President, General Counsel, Corporate Secretary · since 2020
Senior Vice President Finance - Global Controller · since 2014
Lead Independent Director · since 2016
Mary Ellen Coe
Director · since 2019
Thomas R. Cech
Independent Director · since 2009
Independent Director · since 2015
Independent Director · since 2007
Independent Director · since 2017
Paul B. Rothman
Independent Director · since 2015
Independent Director · since 1995
Independent Director · since 2020
Legal address
c/o C T Corporation System
820 Bear Tavern Road
West Trenton
Trenton, NJ 08628-1021
US
820 Bear Tavern Road
West Trenton
Trenton, NJ 08628-1021
US
Headquarters
126 East Lincoln Avenue
PO Box 2000
Rahway, NJ 07065-1310
US
PO Box 2000
Rahway, NJ 07065-1310
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||